For almost thirty years, anyone searching for a hair loss drug landed on the same two answers. Minoxidil, approved in 1988. Finasteride, approved in 1997. Nothing else with a genuinely new mechanism made it across the FDA's finish line in between. That's finally starting to change. It's worth being precise about what's actually approved, what's in late-stage trials, and what's still years away — because the gap between those three categories is exactly where a lot of hair loss marketing gets sloppy.

The two drugs that built the category

Minoxidil is the one you can buy without a prescription. It comes in two strengths, 2.0% for women and 5.0% for men, and it's applied directly to the scalp. It works mainly by widening blood vessels. That extra blood flow pushes more hair follicles into the growth phase of the hair cycle, and keeps them there longer. What it doesn't do is touch the hormonal driver of androgenetic alopecia. That's part of why it needs to be used indefinitely. Stop applying it, and the effect fades within a few months, often returning hair to whatever state it would have reached without treatment.

Finasteride works differently, and it's taken differently too. It's an oral prescription drug. It blocks the enzyme that converts testosterone into DHT, the hormone most responsible for shrinking hair follicles in male pattern hair loss. Because it works on androgen pathways, finasteride is prescribed almost exclusively for men. Getting it means a conversation with a prescriber, not a trip to the drugstore shelf. Dutasteride works on a similar principle and blocks the same enzyme more completely. It often comes up as an off-label option when finasteride's results are limited, though it isn't FDA-approved for hair loss specifically the way finasteride is.

Both drugs work. Both have real safety data behind them, spanning decades. But neither one is a new mechanism, and neither addresses every underlying cause of thinning hair. Genetics, hormones, postpartum shedding, stress, and diet can all show up on a scalp in ways minoxidil and finasteride were never designed to touch. That mismatch is a big part of why so many people try one or both, see partial results, and assume they're simply "not a responder" — when the real issue is that the drug was never aimed at their particular cause in the first place.

Combining what already works

Before getting to what's new, it's worth mentioning something that isn't new at all: using minoxidil and finasteride together. Neither drug replaces the other, since they act on different parts of the problem — one improves blood flow and cycle timing, the other blocks a hormone. Real-world data following patients over time has found that combining them produces better, more consistent outcomes than either drug alone, with the large majority of patients tracked over a year showing stable or improved results. That's not a new mechanism, and it's not a reason to stop watching the pipeline. It's just a reminder that the "boring" combination of two 20th-century drugs still outperforms a lot of what gets marketed as innovative.

What's new in the 2026 pipeline

Two candidates account for most of the actual movement this year, and a handful of others are worth knowing by name even though they're further out.

Clascoterone is a topical anti-androgen. Instead of lowering DHT throughout the body the way finasteride does, it blocks androgen receptors directly at the follicle. That local action is the theoretical advantage. Late-2025 trial results told a fairly encouraging story: hair count in the treated areas improved well beyond what placebo produced. A filing for FDA approval is expected this spring. Because clascoterone works locally rather than systemically, it's being discussed as a possible option for women with androgenetic alopecia — a group that, right now, mostly can't use finasteride at all because of its hormonal effects on the body.

PP405 takes a different approach again. Rather than targeting DHT at all, it's designed to reactivate dormant hair follicle stem cells directly. What made early results notable wasn't just that hair grew back — it's how fast that happened. Some men in early trials saw a real increase in hair density within a matter of weeks, not the six to twelve months typical of minoxidil, while people on placebo saw nothing comparable. Larger trials are expected to run through 2026. If that data holds up at scale, this wouldn't just be a better version of an existing drug. It would be a genuinely different biological mechanism, arguably the first real one since finasteride.

A few other names are circulating at dermatology conferences without being anywhere near approval yet. ET-02 is an early-stage candidate exploring a dual pathway that touches both hair growth and pigment. Breezula, a topical anti-androgen similar in concept to clascoterone, reported positive late-stage trial results of its own. Extended-release reformulations of minoxidil are also moving through later-stage development, aiming to solve the "have to use it forever, exactly on schedule" problem rather than inventing a new mechanism. None of these are close enough to approval to build a treatment plan around today, but they're worth recognizing by name, since headlines about them will keep showing up through the rest of the year.

Here's the thing to hold onto through all of it: Phase 3 data and an FDA filing are not the same thing as an approved drug sitting on a pharmacy shelf. It's worth staying skeptical of any headline that blurs that line this year, no matter how promising the underlying trial numbers look.

A different category: JAK inhibitors for alopecia areata

It's easy to see "new FDA-approved hair loss drug" and assume it applies across the board. It doesn't. Baricitinib, ritlecitinib, and deuruxolitinib were approved in 2022, 2023, and 2024. All three are JAK inhibitors, and all three are approved specifically for severe alopecia areata. That's an autoimmune condition, one where the immune system attacks the hair follicle directly, and it has nothing to do with genetics or hormones the way androgenetic alopecia does.

Androgenetic alopecia is the different, more common disease — genetic and hormone-driven, and the kind of thinning minoxidil and finasteride actually target. Someone with alopecia areata typically loses hair in sudden, often round patches, sometimes rapidly, which looks and behaves nothing like the gradual thinning at a part line or temples that's typical of pattern hair loss. None of the three JAK inhibitors are approved for pattern hair loss, and mixing up the two conditions is one of the more common ways people end up pursuing the wrong treatment path entirely — trying a JAK inhibitor for gradual genetic thinning, or trying minoxidil for sudden patchy loss that actually needs a dermatologist's evaluation.

What this looks like depending on what's actually causing it

Everything above describes the drugs themselves, but "hair loss" isn't one condition, and it's worth walking through how the landscape actually applies depending on what's driving it.

• For a man in his late twenties or thirties noticing a receding hairline or thinning crown, this is androgenetic alopecia in its most textbook form, and it's exactly what finasteride and minoxidil were built for. Combination use tends to be the realistic starting point here, with clascoterone and PP405 as names worth watching rather than acting on yet.
• For a woman with gradual, diffuse thinning across the top of the scalp, the picture gets more complicated. Finasteride generally isn't an option, both because of its hormonal effects and because the evidence base in women is thinner. Minoxidil remains available and effective at the 2.0% strength, but this is exactly the gap clascoterone is aiming at — a topical anti-androgen without the systemic hormonal exposure that keeps oral finasteride off the table for most women.
• For someone a few months postpartum watching noticeably more hair come out in the shower, none of this pipeline conversation is really the point. Postpartum shedding is usually telogen effluvium, a temporary shift in the hair cycle triggered by the hormonal drop after birth, and it typically resolves on its own within six to twelve months. Minoxidil can help support the process for someone who wants to do something in the meantime, but the underlying cause here isn't DHT at all, which is exactly why a DHT-blocking drug wouldn't be the first thing to reach for.
• For someone going through perimenopause or menopause, the mechanism sits somewhere between the two patterns above: estrogen decline shifts the balance toward relatively more androgen activity, which can trigger a genetic predisposition to thinning that hadn't shown up before. That's part of why minoxidil, DHT-blocking approaches, and sometimes hormone therapy all come up in the same conversation for this group, rather than one drug being the obvious single answer.

None of these scenarios are addressed by guessing at a product based on which one has the most convincing before-and-after photos. They're addressed by identifying which pattern actually applies before choosing a regimen.

Where personalization and dermatologist support fit in

None of this changes a basic fact about hair loss treatment. The right drug, or the right combination, depends on what's actually driving the shedding in the first place, and that's not always obvious from the mirror. Someone with genetic thinning, someone dealing with postpartum shedding, and someone whose hair loss is driven by menopause are not well served by identical regimens, even if all three happen to be reaching for a bottle labeled "hair growth serum" at the same drugstore.

This is where MDhair's model is built differently from a single product on a shelf. The AI-driven scalp assessment and quiz are designed to flag the likely underlying cause first, before any product gets recommended at all. From there, a treatment kit gets built from the pieces that actually fit: OTC-approved minoxidil where it's appropriate, DHT-blocker serums, supplements, and unlimited dermatologist chat support so the regimen can be adjusted as things change, rather than staying fixed regardless of whether the first attempt is working.

There's a regulatory line worth drawing clearly here, since it matters for what you can reasonably expect from each piece of a regimen. MDhair's own Minoxidil sits on one side of that line — it's an OTC drug, approved specifically for mild-to-moderate androgenetic hair loss, nothing broader than that. Everything else sits on the other side. The serums, shampoos, supplements, and marine collagen in the lineup are cosmetic products. They're formulated to support scalp and hair health, but they aren't medicated, and none of them are positioned to diagnose or cure anything. Supplement ingredients in particular fall outside FDA evaluation the way a drug's active ingredients don't. Practically, that means: if you're pregnant, nursing, or managing an existing medical condition, loop in your doctor before adding anything new to a routine, prescription or otherwise. And if anything in a regimen causes irritation, the right move is to stop and reassess, not to push through it.

The bottom line for 2026

Minoxidil and finasteride are still the only FDA-approved medications built specifically for androgenetic alopecia, and both still work the way they always have. Clascoterone and PP405 are the two candidates closest to actually changing that math, but neither one has cleared the FDA yet, and a longer list of earlier-stage candidates is still years from mattering to anyone outside a clinical trial. JAK inhibitors are approved, just for a different disease entirely, and telling the two conditions apart matters more than most people assume. What hasn't changed, through any of this, is simpler than the pipeline news: matching a treatment to the actual underlying cause, not just the category of drug, is still the step most likely to determine whether any of it works for you.

If you want to start with that step rather than guessing from a shelf full of options, MDhair's free hair and scalp assessment is a reasonable place to begin.

Find the most effective hair growth products for you by taking the free hair assessment.